Document:

Exhibit 10.99

 

AGREEMENT

between

Alcimede
Limited and Rennova Health, Inc.

 

THIS
AGREEMENT is entered into and is effective as of November 1st 2021 between Alcimede Limited, (the “Company”),
a Bahamas based company with its principle place of business at, Suite 104A, Saffrey Square, Bank Lane, PO Box N-9306, Nassau, The Bahamas,
and Rennova Health, Inc. (the “Client”) organized under the laws of the State of Delaware (and/or other wholly owned subsidiary,
or other affiliated business entities), with main offices located at, 400 S. Australian Avenue, West Palm Beach Florida, 33401.

 

This
agreement replaces any previous agreement that exists with Rennova Health, Inc. with any entity for the provision of services by Seamus
Lagan.

 

WITNESSETH

 

WHEREAS,
the Company provides consulting and management services to businesses in connection with their capital structure, business plan and
business opportunities, management, complimentary acquisitions and seeking and securing of investors, financing or buyers; and

 

WHEREAS,
The Client and the Company wish to enter into a relationship pursuant to the terms and conditions of this Agreement whereby the Company
will assist the Client to create and deliver a business that creates value for the Clients Shareholders. The Agreement is approved by
the Board of Directors of Rennova Health, Inc.

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

 

	1.	Engagement.
    Effective on the date hereof, the Client engages the Company to assist it in delivering its business objectives, which includes providing
    assistance with the capital structure of Client, providing management (including officers or directors if required) as may be required
    on a permanent or temporary basis by Client, assisting with finding and completing acquisitions that may be synergistic with the
    growth plans of the Client, the finding and securing of one or more sources of finance that may be required by the Company and assisting
    the Client to consider and structure any finance that may be offered to it.

 

    	1

     

    

 

	2.	Term
    of Engagement. Subject to the provisions of this Agreement, the term of this Agreement shall be three (3) years and shall commence
    on November 1st, 2021 (the “Initial Term”). Unless either party elects to terminate this Agreement at the
    end of the initial or any renewal term by giving the other party written notice of such election at least sixty (60) days before
    the expiration of the then current term, this Agreement shall be deemed to have been renewed for an additional term of one (1) year
    commencing on the day after the expiration of the then current term. Either party may elect not to renew this Agreement with or without
    cause. Upon expiration of this Agreement after notice of non-renewal, Company shall provide Employee all compensation and benefits
    to which Employee is entitled through the date of termination and thereafter Company’s obligation hereunder shall cease.
	 	 
	3.	Fees.
    In consideration of the Company’s provision of the Services, the Client shall pay or cause to be paid to the Company, in cash,
    the following fees (collectively, the “Fee”):
	 	 
	4.	Compensation

 

	 	a.	Monthly
    Retainer for Services. A non-refundable retainer for services (the monthly “Retainer”) of thirty-one thousand two hundred
    fifty dollars ($31,250) per month will be paid as follows:

 

	 	i.	Fifteen
    thousand six hundred twenty-five dollars ($15,625) will be paid on or before the 15th day of each month; and
	 	 	 
	 	ii.	Fifteen
    thousand six hundred twenty-five dollars ($15,625) will be paid on or before the last working day of each month.

 

	 	b.	Expenses.
    The Client shall reimburse Company for all expenses incurred in connection with duties on behalf of the Company up to $2,500 in one
    calendar month, provided that Employee shall keep, and present to the Client, records and receipts relating to reimbursable expenses
    incurred by Company. The Company will seek pre-approval from the Client for any exceptional expenses or additional costs which Company
    may from time to time propose to Client. Client will have no liability to Company unless pre-approval for certain expenses is granted.

 

	5.	Consultant.
    The Client agrees that the Company will be acting as its consultant in providing the Services, and that, to this end, any and all
    forms of correspondence or communication, as well as dialogue, (altogether referred to as the “Discussions”) will pass
    via the Client. The Company shall obtain the Clients’ prior consent before engaging in such Discussions and Company has no
    authority or right to bind the Client to any agreement without prior approval.
	 	 
	6.	Independent
    Contractor. The Company is acting as an independent contractor hereunder with duties owing solely to the Client. Nothing contained
    herein, expressed or implied, shall create or be construed to impose upon the Company or any of its affiliates, or their respective
    officers, directors, employees or stockholders, any fiduciary or agency relationship or obligation.

 

    	2

     

    

 

	7.	Limitation
    of Liability. The Client agrees that the Company shall have no liability to the Client or any of its affiliates or any third
    party, including, without limitation, any officer, director, employee or stockholder of the Client or any of their respective affiliates,
    for any decision or recommendation made or omitted to be made or any action or failure to act in connection with the Services or
    this Agreement; provided that the foregoing limitation on liability shall not apply to any decision or recommendation made or omitted
    to be made by the Company or any action or failure to act by the Company in connection with this Agreement that is finally held by
    a court of competent jurisdiction to have resulted primarily from the gross negligence or willful misconduct of the Company; provided
    further that notwithstanding anything to the contrary contained herein, in no event will the Company have any liability to the Client
    or any of its affiliates or shareholders or any third party for any consequential, special, punitive or incidental damages.
	 	 
	8.	Information
    Provided to the Company. The Client will furnish the Company with such information about it as the Client believes is necessary
    to the provision of the Services (all information so furnished being herein referred to as the “Information”). The Client
    recognizes and confirms that the Company (i) will use and rely primarily on the Information and the information available from generally
    recognized public sources in performing the Services, without having independently verified the same, (ii) does not assume responsibility
    for the accuracy or completeness of the Information, and (iii) will not make an evaluation or appraisal of any assets of the Client.
    The Company agrees to treat all material, non-public Information in a confidential manner
	 	 
	9.	Confidentiality;
    Non-Disclosure.

 

	 	a)	Confidential
    Information. “Confidential Information” means any information about the Client, or any of its customers, clients,
    suppliers, or vendors in any form, however and whenever acquired, that is not generally known to business competitors or the general
    public, and shall include without limitation: (i) confidential, secret, and/or proprietary knowledge, data, or information; (ii)
    any “trade secret,” as that term is defined by the Florida Uniform Trade Secrets Act (“FUTSA”), § 688.000,
    et seq., or as defined by any other state or federal law governing trade secrets, including the Uniform Trade Secrets Act; (iii)
    inventions, ideas, products, processes, formulas, patterns, compilations, devices, methods, techniques, processes, data, research,
    programs, know-how, improvements, discoveries, computer programs, source codes, and database structure; (iv) business methods, operations,
    plans, projects, finances, prices and costs, sales and shipping information/techniques, market studies, competitive analyses, accounts
    receivable or payable, billing methods, pricing policies, and other non-public financial information; (v) information concerning
    internal affairs, memoranda, policies, legal affairs, and security methods; and (vi) customer, client, vendor, and supplier names
    and addresses, lists, financial information, data, purchasing and supply histories

 

    	3

     

    

 

	 	b)	Company
    Obligations. During the course of this agreement with the Client, Company will be given and receive access to Confidential Information.
    At all times during and subsequent to this agreement, Company will not, directly or indirectly, disclose, discuss, publish, disseminate,
    or otherwise use or suffer to be used in any manner, any Confidential Information, except as otherwise allowed by this Agreement.
    Company will use Confidential Information only for the contemplated purposes for the sole benefit of the Client and will disclose
    Confidential Information only as required in the course and scope of Client’s job duties. Immediately upon the termination
    of this agreement for any reason or at any time when requested by the Client, Company will return all Confidential Information to
    the Client. Company further acknowledges and agrees that a breach of any of the provisions of paragraphs 9 will leave the Client
    without an adequate remedy at law and therefore agrees that the remedy provided for herein is equitable and just, namely: (1) the
    Client shall be entitled to an immediate injunction to prohibit the further breach of any of these provisions, (2) the Client shall
    be entitled to prosecute to the extent allowed by law, and (3) the Client shall be entitled to recover fees associated with the cost
    of prosecution and damages.
	 	 	 
	 	c)	Ownership
    of Client Property and Assignment of Intellectual Property. All Confidential Information is and shall remain the Client’s
    property and Company will not remove any Confidential Information from Client premises.

 

	10.	Indemnification.
    The Client agrees to indemnify and hold harmless the Company and its affiliates, and each of their respective officers, directors,
    employees or stockholders (the Company and each such person being referred to herein as the “Indemnified Party”), from
    and against any and all losses, claims, damages, fines, liabilities, judgments, or amounts paid in settlement (or actions, proceedings
    or investigations in respect thereof), to which such Indemnified Party may become subject under any applicable federal or state law,
    or otherwise, related to or arising out of any Financing or Acquisition or the Services hereunder. The Client agrees to reimburse
    the Company and any Indemnified Party for all expenses (including reasonable attorney’s fees and expenses) as they are incurred
    in connection with the investigation of, preparation for or defense of any such pending or threatened loss, claim, damage, liability
    or any action or proceeding arising therefrom, whether or not such Indemnified Party is a party. The Client will not be liable under
    the foregoing indemnification provision to the extent that any loss, claim, damage, liability, fine, judgment or expense is found
    in a final non-appealable judgment by a court of competent jurisdiction to have resulted primarily from the Company’s gross
    negligence or willful misconduct. This indemnification shall survive termination of the Company’s Services under this Agreement
    and shall be binding upon any successors or assigns of the Client.

 

    	4

     

    

 

	11.	Restrictive
    Covenants. Company agrees to the following Restrictive Covenants:

 

	 	a.	Non-Compete.
    During the term of this agreement and for a period of twelve (12) months after the termination of this agreement with the Client
    for any reason whatsoever (“Restricted Period”), Company will not, directly or indirectly (on Company’s own behalf
    or on behalf of any other person or entity) engage in any business or own an interest in any business, including but not limited
    to, a sole proprietorship, partnership, corporation, joint stock company, joint venture, limited liability company, trust or other
    form of business entity, unincorporated organization, whether as an individual proprietor, partner, shareholder, joint venturer,
    member, trustee, officer, director, consultant, broker, employee, or in any manner whatsoever (except for an ownership interest not
    exceeding five percent (5%) of a publicly-traded entity), that (i) conducts business within the State of Florida or within a one
    hundred (100) mile radius of any geographic area in which the Client then conducts business and (ii) is competitive with any business
    in which the Client has been engaged at any time during Company’s agreement
	 	 	 
	 	b.	Non-Solicit
    of Employees. During the Restricted Period, Company will not, directly or indirectly (on Company’s own behalf or on behalf
    of any other person or entity) contact, recruit, solicit or otherwise seek to induce any employee or contractor of any to terminate
    his/her employment or engagement with the Client. This covenant applies to any employee or contractor who, at the time of such attempted
    recruitment/hire by Client is currently employed or engaged with the Client or was previously employed or engaged with the Client
    within the eighteen (18) month period immediately preceding the termination of Company’s agreement.
	 	 	 
	 	c.	Non-Solicit
    of Customers/Business Relationships. During the Restricted Period, other than for the benefit of the Client, solicit, contact,
    or do business with (if offered to Company, with or without solicitation) any customer of the Client regarding any business engaged
    in by the Client; and/or divert or attempt to divert from the Client or otherwise interfere with any business relationship between
    the Client and any existing or prospective client or other source of business, investor, customer, client, vendor or other person
    or entity with which the Client maintains or has maintained a business relationship. For purposes of this Agreement, “customer”
    shall include any specific prospective or existing person or entity with whom the Client has engaged in business at any time during
    Company’s agreement or within the three (3) year period preceding Company’s agreement.
	 	 	 
	 	d.	Reasonableness
    of Restrictive Covenants. Company has carefully read and considered the promises made in this Agreement. Company agrees that
    the promises made in this Agreement are reasonable and necessary for protection of the Client’s legitimate business interests,
    including but not limited, to its trade secrets; Confidential Information; existing and specific prospective customer relationships;
    productive and competent workforce; and undisrupted workplace. Company further agrees that prior to signing this Agreement, it has
    been provided a reasonable time to review the Agreement and an opportunity to consult separate counsel concerning the terms of this
    Agreement.

 

    	5

     

    

 

	 	e.	Savings
    Clause; Full Effect. If it is determined by a court of competent jurisdiction that any restriction in this Section 7 is excessive
    in duration or scope or is unreasonable or unenforceable, it is the intention of the Parties that such restriction may be modified
    or amended by the court to render it enforceable to the maximum extent permitted by law. Additionally, the Client shall be entitled
    to the full benefit of the promises stated in this Agreement. Accordingly, if Company violates any or all of the covenants, this
    Agreement shall remain in full force and effect beyond the expiration of the term of the promise, such that the Client receives the
    full benefit of its bargain. Company’s obligations under this Agreement shall survive the termination of Company’s agreement
    with the Client.
	 	 	 
	 	f.	Independent
    Obligations. The restrictive covenants contained in this Agreement are independent of any other obligations owed by the Client
    to Company. The existence of any claim or cause of action by Company against the Client, whether based on this Agreement or otherwise
    created, shall not create a defense to the enforcement by the Client of any restrictive covenants contained herein.
	 	 	 
	 	g.	Injunction.
    Company acknowledges that a breach of the restrictive covenants contained in this Agreement will cause irreparable damage to the
    Client. Accordingly, in the event of a breach or threatened breach of the restrictive covenants contained in this Agreement, the
    Client shall be entitled to preliminary and permanent injunctive relief against Company and all persons or entities acting in concert
    with Company, to restrain the violation.

 

	12.	Company
    Representation. The Company represents and warrants to the Client that there is no legal impediment to it entering into, or performing
    its obligations under, this Agreement, and that entering into this Agreement will not violate any agreement to which Company is a
    party or any other legal restriction. The Company further represents and warrants that it will not use or disclose any confidential
    information of any prior employer or other person or entity during the term of this agreement with the Client.
	 	 
	13.	Amendment.
    This Agreement may only be amended by a written agreement signed by both parties.
	 	 
	14.	Assignment.
    Client consents and agrees that the Company may assign their rights within this agreement herein with advance written consent.
	 	 
	15.	Governing
    Law. This Agreement shall be governed by the internal laws of the Florida without regard to its law of conflicts. The Company
    waives any objection to venue or jurisdiction and any objection based on a more convenient forum in any action under this Agreement.
	 	 
	16.	Notices.
    All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to have been
    duly given when

 

    	6

     

    

 

	 	(a)	acknowledged
    as received by the other party as a scanned and email document
	 	(b)	or
    by any other means of delivery service for which the sender received a receipt of delivery

 

	 	The
    Client:	Rennova
    Health, Inc
	 	 	400
    S Australian Avenue
	 	 	West
    Palm Beach Florida
	 	 	 
	 	The
    Company:	Alcimede
    Limited
	 	 	Suite
    104A, Saffrey Square,
	 	 	Bank
    Lane,
	 	 	PO
    Box N-9306,
	 	 	Nassau,
    The Bahamas
	 	 	Attention:
    Seamus Lagan
	 	 	Email
    s.lagan@btinternet.com

 

	17.	Entire
    Agreement. This Agreement supersedes all prior agreements between the parties with respect to its subject matter and constitutes
    a complete and exclusive statement of the terms of the agreement between the parties with respect to its subject or its subject matter.

 

IN
WITNESS WHEREOF, the parties have duly signed this Agreement as of the day and year first above written.

 

	THE
    CLIENT:	 
	Rennova
    Health, Inc	 
	 	 	 
	 /s/	 Gary
    Blum	 
	By; 	Gary
    Blum – Independent Director and Head of Compensation Committee	 

 

	THE
    COMPANY:	 
	Alcimede
    Limited	 
	 	 	 
	 /s/	 Seamus
    Lagan	 
	By:	Seamus
    Lagan	 

 

    	7Exhibit
4.3

 

DESCRIPTION
OF THE REGISTRANT’S SECURITIES

REGISTERED
PURSUANT TO SECTION 12 OF THE

SECURITIES
EXCHANGE ACT OF 1934

 

The
following is a general description of the common stock of RespireRx Pharmaceuticals Inc. (the “Company”) and does not purport
to be complete. For a complete description of the terms and provisions of the common stock, refer to the Company’s Second Restated
Certificate of Incorporation, as amended to date (the “Certificate of Incorporation”) and By-Laws of the Company, as amended
(the “Bylaws”), each of which is an exhibit incorporated by reference into the Annual Report on Form 10-K of which this exhibit
is a part. This summary is qualified in its entirety by reference to these documents.

 

Authorized
and Outstanding Capital Stock

 

The
Company is authorized to issue a total of 2,005,000,000 shares of capital stock, with a par value of $0.001 per share. Of the authorized
amount, 2,000,000,000 of the shares are designated as Common Stock and 5,000,000 of the shares are designated as preferred stock.

 

Description
of Common Stock

 

General.
Each share of the Company’s Common Stock has the same rights and privileges. Holders of the common stock do not have any preferences
or any preemptive, redemption, subscription, conversion or exchange rights. All outstanding shares of common stock are fully paid and
non-assessable. The Company’s Common Stock is quoted on the OTCQB, under the symbol “RSPI.”

 

Voting
Rights. The holders of Common Stock are entitled to vote upon all matters submitted to a vote of stockholders and are entitled to
one vote for each share of Common Stock held. There is no cumulative voting.

 

Dividends.
The Company has never paid cash dividends on its Common Stock and does not anticipate paying such dividends in the foreseeable future.
The payment of dividends, if any, will be determined by the Board in light of conditions then existing and may be paid on the Common
Stock subject to the prior rights and preferences, if any, applicable to shares of preferred stock or any series of preferred stock,
when and if declared by the Board, out of funds legally available therefor.

 

Liquidation
and Distribution. If the Company voluntarily or involuntarily liquidates, dissolves or winds-up, or upon any distribution of assets,
the holders of Common Stock will be entitled to receive, after distribution in full of the preferential amounts, if any, to be distributed
to the holders of preferred stock or any series of preferred stock, all of the remaining assets available for distribution equally and
ratably in proportion to the number of shares of Common Stock held by them.

 

Material
Limitation or Qualification of Rights of Common Stock

 

Preferred
Stock, Generally. The Company may issue preferred stock with such powers, preferences, rights, qualifications, limitations, and restrictions
as the Board may, without prior stockholder approval, establish. The existence, and potential future issuance, of shares of preferred
stock by the Company could result in substantial dilution of the economic and governance rights of holders of the Company’s common
stock.

 

The
Company’s authorized shares of preferred stock
are designated into series as follows: 3,000 shares of Series H 2% Voting, Non-Participating Convertible Preferred Stock, 37,500 shares
as Series B Convertible Preferred Stock (“Series B Preferred Stock”), 1,700 shares as Series G 1.5% Convertible Preferred
Stock (“Series G Preferred Stock”), 1,250,000 shares as 9% Cumulative Convertible Preferred Stock (“9% Preferred Stock”),
205,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred Stock”), and 3,505,800 shares are undesignated
and may be issued with such rights and powers as the Board may designate.

 

    	 

     

    

 

Series
H Preferred Stock. No shares of Series H Preferred Stock are issued and outstanding or accrued as dividends as all outstanding
shares of Series H Preferred Stock inclusive of accrued dividends converted into units that resulted in the issuance of 25,377,426 shares
of Common Stock and warrants to purchase 25,377,426 shares of Common Stock. Each share of Series H Preferred Stock is convertible into
15,625 units at an effective conversion price of $0.064 per unit, with each unit comprising one share of Common Stock and one warrant
exercisable for one share of Common Stock. Each share of Series H Preferred Stock entitles the holder to that number of votes equal to
two times the number of shares of Common Stock into which it is convertible. In the event of any liquidation or winding up of the Company
prior to and in preference to any junior securities, the holders of the Series H Preferred Stock will be entitled to receive in preference
to the holders of any junior securities a per share amount equal to the $0.001, plus any accrued and unpaid dividends.

 

Series
B Preferred Stock. 37,500 shares of Series B Preferred Stock are issued and outstanding. Each share of Series
B Preferred Stock is convertible into approximately 0.000030 shares of common stock at an effective conversion price of $22,083.75 per
share of common stock, which is subject to adjustment under certain circumstances. As of December 31, 2021, the shares of Series B Preferred
Stock outstanding are convertible into 1 share of Common Stock. Shares of Series B Preferred Stock do not entitle the holder to voting
rights. The Company may redeem the Series B Preferred Stock for $25,001, equivalent to $0.6667 per share, an amount equal to the liquidation
preference, at any time upon 30 days prior notice.

 

Series
G Preferred Stock. No shares of Series G Preferred Stock are issued and outstanding. If issued, each share of Series G Preferred
Stock is convertible into that number of shares of Common Stock determined by dividing $1,000 by an initial conversion price of $0.033.
The conversion price with respect to a share of Series G Preferred Stock is subject to adjustment upon certain events that occur while
such share is outstanding, pursuant to Section 7 of the Certificate of Designation for the Series G Preferred Stock (see Exhibit 3.7
to the Company’s Annual Report on Form 10-K of which this exhibit is a part). As of December 31, 2020, the conversion price with
respect to Series G Preferred Stock is not subject to adjustment because no shares of Series G Preferred Stock are outstanding. If issued,
each outstanding share of Series G Preferred Stock, prior to the date such share is eligible for conversion, entitles the holder to 30,303
votes per share (which may be subject to adjustment as described above), and thereafter, each share entitles the holder to voting rights
on an as-converted basis.

 

9%
Preferred Stock. No shares of 9% Preferred Stock are issued and outstanding. If issued, each share of 9% Preferred Stock is
convertible into shares of common stock according to a conversion rate subject to adjustment upon the occurrence of certain events, including
a reverse stock split, as set forth under the Certificate of Incorporation (see Exhibit 3.1 to the Company’s Annual Report on Form
10-K of which this exhibit is a part). Thereunder, each share of 9% Preferred Stock is convertible into that number of shares of common
stock determined by dividing $1.00 by a conversion rate of $1.50, subject to adjustment pursuant to the reverse stock splits effected
by the Company on September 1, 2016 and January 5, 2021, whereby, on September 1, 2016 each 325 shares of Common Stock was exchanged
and combined into one share of Common Stock and on January 5, 2021, each 10 shares of Common Stock was exchanged and combined into one
share of Common Stock. Shares of 9% Preferred Stock do not entitle the holder to voting rights.

 

Series
A Preferred Stock. No shares of Series A Preferred Stock are issued and outstanding. Shares of Series A Preferred Stock do
not entitle the holder to voting rights, except to the extent the holder would be entitled to vote with the holders of Common Stock as
set forth in the Certificate of Designation for the Series A Preferred Stock. 

 

Anti-Takeover
Provisions in the Certificate of Incorporation and Bylaws

 

Certain
provisions of our Certificate of Incorporation and Bylaws summarized below may delay, defer or prevent a tender offer or takeover attempt,
including attempts that might result in a premium over the market price for the Company’s securities.

 

Our
Certificate of Incorporation and Bylaws provide: (i) that the Company may issue preferred stock with such powers, preferences, rights,
qualifications, limitations, and restrictions as the Board may, without prior stockholder approval, establish, as described above; and
(ii) that special meetings of stockholders may only be called by the chairman of the Board, the president, the secretary, a majority
of the members of the Board or the holders of a majority of the shares of Common Stock then outstanding.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]